Dr. Shirley Bartido joined Cellectis as Director of Regulatory Affairs in 2016. Dr. Bartido holds a PhD in Immunology and a MBA in Pharmaceutical Management from Rutgers University. She completed her doctoral studies at New York University elucidating an alternative Class II processing and presentation pathway utilizing a viral antigen. Her postdoctoral work at Memorial Sloan Kettering Cancer Center involved the development of DNA vaccines for the treatment of melanoma using the melanosomal antigen tyrosinase. Following her postdoctoral work, she joined the Carl Icahn Institute of Gene Therapy and Molecular Medicine as an Assistant Professor to serve as the Assistant Director of the Gene Therapy Immunology Core Laboratory. In this role, she developed several immunomonitoring tools for assaying efficacy of adenoviral directed immunotherapies using AdV-IL-12 vectors targeting metastatic liver cancer. This was followed by an 11-year role as the Senior Quality Manager of the Cell Therapy and Cell Engineering Facility at Memorial Sloan Kettering Cancer Center. In this role, she developed the QA program for the development and GMP manufacturing of autologous CD19 Chimeric Antigen Receptor T-cell therapies for several clinical trials which targeted several indications in leukemia and prostate cancer as well as gene therapy for the treatment of B-Thalassemia using lentiviral transduced CD34+ HPSCs. She was an integral member in the design and construction of a state of the art GMP facility at MSKCC. Presently, she is the Director of Regulatory Affairs at Cellectis Inc. The company’s platform is gene editing using TALEN based technology in the development of allogeneic CAR T-cells targeting hematological malignancies. She has authored several peer-reviewed publications in several well cited scientific journals and has been invited as speaker in many well attended conferences.